J
Jean-Jacques Body
Researcher at Université libre de Bruxelles
Publications - 397
Citations - 21506
Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells.
Fabrice Journe,Jean Claude Dumon,Naima Kheddoumi,Jack Jeffrey Fox,Ioanna Laïos,Guy Leclercq,Jean-Jacques Body +6 more
TL;DR: Calcium released during the process of metastatic bone destruction could modulate the functions of the estrogen receptor, a key receptor involved in breast cancer cells growth and function, and thus participate in the pathogenesis of tumor-induced osteolysis.
Journal ArticleDOI
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
TL;DR: Zoledronic acid is the first bisphosphonate shown to have a direct clinical benefit in the treatment of osteoblastic bone metastases, reducing the number and rate of skeletal events in prostate cancer patients with metastatic bone disease.
Journal ArticleDOI
Efficacy and safety of the bisphosphonate Tiludronate for the treatment of tumor-associated hypercalcemia
TL;DR: Compared with aminobisphosphonates, tiludronate is not indicated for the treatment of tumor-associated hypercalcemia because of the need for high iv doses which are potentially nephrotoxic.
Journal ArticleDOI
Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients.
Valérie Huyge,Camilo Garcia,Jean Alexiou,Lieveke Ameye,Bruno Vanderlinden,Marc Lemort,Pierre Bergmann,Ahmad Awada,Jean-Jacques Body,Patrick Flamen +9 more
TL;DR: Whole-body FDG-PET allows frequent heterogeneous responses after systemic therapy to be identified in bone-dominant metastatic breast cancer patients.
Journal ArticleDOI
Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts.
Hichame Id Boufker,Laurence Lagneaux,Hussein Fayyad-Kazan,Bassam Badran,Mehdi Najar,Murielle Wiedig,Ghanem Elias Ghanem,Guy Laurent,Jean-Jacques Body,Fabrice Journe +9 more
TL;DR: A new role for FXR is supported in the modulation of osteoblast/adipocyte balance: its activation stimulates RUNX2-mediated osteoblastic differentiation of BMSC, whereas its inhibition leads to an adipocyte-like phenotype.